Study Comparing Transdermal Granisetron Patch and Intravenous Ondansetron for Preventing Nausea and Vomiting in Adults Undergoing Chemotherapy and Stem Cell Transplant

What this Trial Is About

Patients undergoing autologous or allogeneic hematopoietic stem cell transplant HSCT often receive preparative chemotherapy that causes significant chemotherapy-induced nausea and vomiting CINV. Current treatments to reduce CINV in these patients are not fully effective and may cause side effects or have drug interactions. This study compares two anti-nausea medications to find out which works better and is safer for these patients. The study randomly assigns patients to one of two groups one group uses a transdermal granisetron patch applied one to two days before chemotherapy and again seven days later, combined with intravenous dexamethasone the other group receives intravenous ondansetron with intravenous dexamethasone following standard dosing schedules. Rescue anti-nausea medications can be used as needed during chemotherapy and for seven days afterward. Patient care, chemotherapy, and lab monitoring follow usual procedures throughout the study. Participants will be monitored daily for nausea, vomiting, and side effects during chemotherapy and for a week after. A quality of life questionnaire MDASI-BMT is completed seven days after the transplant infusion. Researchers will compare how many patients avoid vomiting and rescue medication use during several timeframes, assess side effects, and evaluate quality of life up to about a month after transplant. The study runs until July 2026 and follows patients closely to understand the treatments effects.

BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron